Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder

The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1

SABIC launches first fluorine-free polycarbonate resin to boost medical device safety

The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards

Novo Nordisk files FDA application for once-weekly obesity drug CagriSema

If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection

Thyrocare appoints Dr Ramesh Kinha as COO

Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems

AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder

The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India

Godavari Biorefineries launches US biotech arm to advance novel cancer therapies

The move strengthens GBL’s clinical-stage presence in the United States

Merck’s KEYTRUDA–Padcev combo delivers survival gains in Phase 3 bladder cancer trial

Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer

The combination also outperformed chemotherapy on another important secondary endpoint

FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer

Patients with BRCA mutations often face aggressive disease and poor prognosis

Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board

Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute